nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—PDGFRB—sarcoma	0.184	0.426	CbGaD
Bosutinib—BTK—Mitoxantrone—sarcoma	0.183	0.842	CbGbCtD
Bosutinib—SRC—sarcoma	0.149	0.343	CbGaD
Bosutinib—EGFR—sarcoma	0.0999	0.231	CbGaD
Bosutinib—CYP3A4—Thiotepa—sarcoma	0.00693	0.0319	CbGbCtD
Bosutinib—ABCB1—Dactinomycin—sarcoma	0.00556	0.0256	CbGbCtD
Bosutinib—ABCB1—Mitoxantrone—sarcoma	0.00497	0.0229	CbGbCtD
Bosutinib—ABCB1—Vincristine—sarcoma	0.00342	0.0157	CbGbCtD
Bosutinib—ABCB1—Etoposide—sarcoma	0.00314	0.0144	CbGbCtD
Bosutinib—CYP3A4—Mitoxantrone—sarcoma	0.00298	0.0137	CbGbCtD
Bosutinib—ABCB1—Doxorubicin—sarcoma	0.00214	0.00984	CbGbCtD
Bosutinib—CYP3A4—Vincristine—sarcoma	0.00205	0.00943	CbGbCtD
Bosutinib—CYP3A4—Etoposide—sarcoma	0.00188	0.00864	CbGbCtD
Bosutinib—CYP3A4—Doxorubicin—sarcoma	0.00128	0.00589	CbGbCtD
Bosutinib—Vandetanib—TEK—sarcoma	0.00124	0.267	CrCbGaD
Bosutinib—Vandetanib—PDGFRB—sarcoma	0.000796	0.172	CrCbGaD
Bosutinib—Vandetanib—SRC—sarcoma	0.000642	0.139	CrCbGaD
Bosutinib—Vandetanib—KDR—sarcoma	0.000603	0.13	CrCbGaD
Bosutinib—Vandetanib—VEGFA—sarcoma	0.000511	0.11	CrCbGaD
Bosutinib—Vandetanib—EGFR—sarcoma	0.000431	0.0932	CrCbGaD
Bosutinib—STK24—Teniposide—Etoposide—sarcoma	0.00042	0.134	CbGdCrCtD
Bosutinib—Gefitinib—EGFR—sarcoma	0.00041	0.0885	CrCbGaD
Bosutinib—CASK—Teniposide—Etoposide—sarcoma	0.000271	0.0866	CbGdCrCtD
Bosutinib—CDK2—Vinblastine—Vincristine—sarcoma	0.000265	0.0846	CbGdCrCtD
Bosutinib—WEE1—Daunorubicin—Epirubicin—sarcoma	0.000246	0.0787	CbGdCrCtD
Bosutinib—WEE1—Daunorubicin—Doxorubicin—sarcoma	0.000228	0.0728	CbGdCrCtD
Bosutinib—CHEK2—Vindesine—Vincristine—sarcoma	0.000187	0.0598	CbGdCrCtD
Bosutinib—ERBB3—Podofilox—Etoposide—sarcoma	0.000175	0.0558	CbGdCrCtD
Bosutinib—Discomfort—Mitoxantrone—sarcoma	0.000139	0.00191	CcSEcCtD
Bosutinib—Renal failure acute—Epirubicin—sarcoma	0.000139	0.0019	CcSEcCtD
Bosutinib—Anaphylactic shock—Vincristine—sarcoma	0.000139	0.0019	CcSEcCtD
Bosutinib—Oedema—Vincristine—sarcoma	0.000139	0.0019	CcSEcCtD
Bosutinib—Infection—Vincristine—sarcoma	0.000138	0.00189	CcSEcCtD
Bosutinib—Nervous system disorder—Vincristine—sarcoma	0.000136	0.00187	CcSEcCtD
Bosutinib—Decreased appetite—Thiotepa—sarcoma	0.000136	0.00186	CcSEcCtD
Bosutinib—Thrombocytopenia—Vincristine—sarcoma	0.000136	0.00186	CcSEcCtD
Bosutinib—Hepatic function abnormal—Doxorubicin—sarcoma	0.000136	0.00186	CcSEcCtD
Bosutinib—Oedema—Mitoxantrone—sarcoma	0.000135	0.00185	CcSEcCtD
Bosutinib—Anaphylactic shock—Mitoxantrone—sarcoma	0.000135	0.00185	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Thiotepa—sarcoma	0.000135	0.00185	CcSEcCtD
Bosutinib—Decreased appetite—Dactinomycin—sarcoma	0.000135	0.00185	CcSEcCtD
Bosutinib—Fatigue—Thiotepa—sarcoma	0.000135	0.00185	CcSEcCtD
Bosutinib—Dysgeusia—Etoposide—sarcoma	0.000135	0.00185	CcSEcCtD
Bosutinib—Renal impairment—Epirubicin—sarcoma	0.000135	0.00185	CcSEcCtD
Bosutinib—Infection—Mitoxantrone—sarcoma	0.000134	0.00184	CcSEcCtD
Bosutinib—Fatigue—Dactinomycin—sarcoma	0.000134	0.00184	CcSEcCtD
Bosutinib—Pain—Thiotepa—sarcoma	0.000134	0.00183	CcSEcCtD
Bosutinib—Back pain—Etoposide—sarcoma	0.000133	0.00183	CcSEcCtD
Bosutinib—Pain—Dactinomycin—sarcoma	0.000133	0.00182	CcSEcCtD
Bosutinib—Thrombocytopenia—Mitoxantrone—sarcoma	0.000132	0.00181	CcSEcCtD
Bosutinib—Skin disorder—Mitoxantrone—sarcoma	0.000131	0.0018	CcSEcCtD
Bosutinib—Feeling abnormal—Thiotepa—sarcoma	0.000129	0.00177	CcSEcCtD
Bosutinib—Renal failure acute—Doxorubicin—sarcoma	0.000128	0.00176	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Epirubicin—sarcoma	0.000128	0.00176	CcSEcCtD
Bosutinib—Feeling abnormal—Dactinomycin—sarcoma	0.000128	0.00175	CcSEcCtD
Bosutinib—Gastrointestinal pain—Thiotepa—sarcoma	0.000128	0.00175	CcSEcCtD
Bosutinib—Ill-defined disorder—Etoposide—sarcoma	0.000128	0.00175	CcSEcCtD
Bosutinib—Anaemia—Etoposide—sarcoma	0.000127	0.00175	CcSEcCtD
Bosutinib—Gastrointestinal pain—Dactinomycin—sarcoma	0.000127	0.00174	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Vincristine—sarcoma	0.000126	0.00173	CcSEcCtD
Bosutinib—Renal impairment—Doxorubicin—sarcoma	0.000125	0.00171	CcSEcCtD
Bosutinib—Urticaria—Thiotepa—sarcoma	0.000124	0.0017	CcSEcCtD
Bosutinib—Malaise—Etoposide—sarcoma	0.000124	0.0017	CcSEcCtD
Bosutinib—Face oedema—Epirubicin—sarcoma	0.000124	0.0017	CcSEcCtD
Bosutinib—Body temperature increased—Thiotepa—sarcoma	0.000124	0.0017	CcSEcCtD
Bosutinib—Abdominal pain—Thiotepa—sarcoma	0.000124	0.0017	CcSEcCtD
Bosutinib—Leukopenia—Etoposide—sarcoma	0.000123	0.00169	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000123	0.00169	CcSEcCtD
Bosutinib—Abdominal pain—Dactinomycin—sarcoma	0.000123	0.00168	CcSEcCtD
Bosutinib—Body temperature increased—Dactinomycin—sarcoma	0.000123	0.00168	CcSEcCtD
Bosutinib—Decreased appetite—Vincristine—sarcoma	0.000121	0.00165	CcSEcCtD
Bosutinib—Dyspnoea—Mitoxantrone—sarcoma	0.00012	0.00165	CcSEcCtD
Bosutinib—Cough—Etoposide—sarcoma	0.00012	0.00165	CcSEcCtD
Bosutinib—ERBB3—Vinblastine—Vincristine—sarcoma	0.00012	0.0384	CbGdCrCtD
Bosutinib—Blood creatinine increased—Epirubicin—sarcoma	0.00012	0.00165	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Vincristine—sarcoma	0.00012	0.00164	CcSEcCtD
Bosutinib—Fatigue—Vincristine—sarcoma	0.00012	0.00164	CcSEcCtD
Bosutinib—Dehydration—Epirubicin—sarcoma	0.000119	0.00163	CcSEcCtD
Bosutinib—Pain—Vincristine—sarcoma	0.000119	0.00163	CcSEcCtD
Bosutinib—Gastrointestinal haemorrhage—Doxorubicin—sarcoma	0.000119	0.00163	CcSEcCtD
Bosutinib—CHEK2—Vinorelbine—Vincristine—sarcoma	0.000118	0.0377	CbGdCrCtD
Bosutinib—CHEK2—Teniposide—Etoposide—sarcoma	0.000118	0.0377	CbGdCrCtD
Bosutinib—CHEK2—Podofilox—Etoposide—sarcoma	0.000118	0.0377	CbGdCrCtD
Bosutinib—Decreased appetite—Mitoxantrone—sarcoma	0.000117	0.00161	CcSEcCtD
Bosutinib—Chest pain—Etoposide—sarcoma	0.000117	0.00161	CcSEcCtD
Bosutinib—Abdominal pain upper—Epirubicin—sarcoma	0.000117	0.00161	CcSEcCtD
Bosutinib—Fatigue—Mitoxantrone—sarcoma	0.000116	0.0016	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000116	0.0016	CcSEcCtD
Bosutinib—Discomfort—Etoposide—sarcoma	0.000116	0.00159	CcSEcCtD
Bosutinib—Pain—Mitoxantrone—sarcoma	0.000116	0.00158	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Epirubicin—sarcoma	0.000115	0.00158	CcSEcCtD
Bosutinib—Nasopharyngitis—Epirubicin—sarcoma	0.000115	0.00157	CcSEcCtD
Bosutinib—Face oedema—Doxorubicin—sarcoma	0.000114	0.00157	CcSEcCtD
Bosutinib—Gastrointestinal pain—Vincristine—sarcoma	0.000113	0.00156	CcSEcCtD
Bosutinib—Gastritis—Epirubicin—sarcoma	0.000113	0.00156	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Epirubicin—sarcoma	0.000113	0.00155	CcSEcCtD
Bosutinib—Anaphylactic shock—Etoposide—sarcoma	0.000112	0.00154	CcSEcCtD
Bosutinib—Asthenia—Thiotepa—sarcoma	0.000112	0.00154	CcSEcCtD
Bosutinib—Infection—Etoposide—sarcoma	0.000112	0.00153	CcSEcCtD
Bosutinib—Asthenia—Dactinomycin—sarcoma	0.000111	0.00153	CcSEcCtD
Bosutinib—Feeling abnormal—Mitoxantrone—sarcoma	0.000111	0.00153	CcSEcCtD
Bosutinib—Blood creatinine increased—Doxorubicin—sarcoma	0.000111	0.00152	CcSEcCtD
Bosutinib—Influenza—Epirubicin—sarcoma	0.000111	0.00152	CcSEcCtD
Bosutinib—Pruritus—Thiotepa—sarcoma	0.000111	0.00152	CcSEcCtD
Bosutinib—Gastrointestinal pain—Mitoxantrone—sarcoma	0.00011	0.00151	CcSEcCtD
Bosutinib—Dehydration—Doxorubicin—sarcoma	0.00011	0.00151	CcSEcCtD
Bosutinib—Thrombocytopenia—Etoposide—sarcoma	0.00011	0.00151	CcSEcCtD
Bosutinib—Body temperature increased—Vincristine—sarcoma	0.00011	0.0015	CcSEcCtD
Bosutinib—Abdominal pain—Vincristine—sarcoma	0.00011	0.0015	CcSEcCtD
Bosutinib—Skin disorder—Etoposide—sarcoma	0.000109	0.0015	CcSEcCtD
Bosutinib—Abdominal pain upper—Doxorubicin—sarcoma	0.000108	0.00149	CcSEcCtD
Bosutinib—Urticaria—Mitoxantrone—sarcoma	0.000107	0.00147	CcSEcCtD
Bosutinib—Diarrhoea—Thiotepa—sarcoma	0.000107	0.00147	CcSEcCtD
Bosutinib—Abdominal pain—Mitoxantrone—sarcoma	0.000107	0.00146	CcSEcCtD
Bosutinib—Body temperature increased—Mitoxantrone—sarcoma	0.000107	0.00146	CcSEcCtD
Bosutinib—Aspartate aminotransferase increased—Doxorubicin—sarcoma	0.000107	0.00146	CcSEcCtD
Bosutinib—Bronchitis—Epirubicin—sarcoma	0.000107	0.00146	CcSEcCtD
Bosutinib—Diarrhoea—Dactinomycin—sarcoma	0.000106	0.00146	CcSEcCtD
Bosutinib—Nasopharyngitis—Doxorubicin—sarcoma	0.000106	0.00145	CcSEcCtD
Bosutinib—Pancytopenia—Epirubicin—sarcoma	0.000105	0.00144	CcSEcCtD
Bosutinib—Gastritis—Doxorubicin—sarcoma	0.000105	0.00144	CcSEcCtD
Bosutinib—Alanine aminotransferase increased—Doxorubicin—sarcoma	0.000105	0.00143	CcSEcCtD
Bosutinib—Neutropenia—Epirubicin—sarcoma	0.000104	0.00142	CcSEcCtD
Bosutinib—Dizziness—Thiotepa—sarcoma	0.000103	0.00142	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Epirubicin—sarcoma	0.000103	0.00141	CcSEcCtD
Bosutinib—Influenza—Doxorubicin—sarcoma	0.000103	0.00141	CcSEcCtD
Bosutinib—Dyspnoea—Etoposide—sarcoma	0.0001	0.00137	CcSEcCtD
Bosutinib—Asthenia—Vincristine—sarcoma	9.95e-05	0.00136	CcSEcCtD
Bosutinib—Vomiting—Thiotepa—sarcoma	9.95e-05	0.00136	CcSEcCtD
Bosutinib—Pneumonia—Epirubicin—sarcoma	9.94e-05	0.00136	CcSEcCtD
Bosutinib—Infestation—Epirubicin—sarcoma	9.88e-05	0.00135	CcSEcCtD
Bosutinib—Infestation NOS—Epirubicin—sarcoma	9.88e-05	0.00135	CcSEcCtD
Bosutinib—Vomiting—Dactinomycin—sarcoma	9.87e-05	0.00135	CcSEcCtD
Bosutinib—Rash—Thiotepa—sarcoma	9.87e-05	0.00135	CcSEcCtD
Bosutinib—Bronchitis—Doxorubicin—sarcoma	9.86e-05	0.00135	CcSEcCtD
Bosutinib—Dermatitis—Thiotepa—sarcoma	9.86e-05	0.00135	CcSEcCtD
Bosutinib—Headache—Thiotepa—sarcoma	9.8e-05	0.00134	CcSEcCtD
Bosutinib—Rash—Dactinomycin—sarcoma	9.79e-05	0.00134	CcSEcCtD
Bosutinib—Decreased appetite—Etoposide—sarcoma	9.77e-05	0.00134	CcSEcCtD
Bosutinib—Pancytopenia—Doxorubicin—sarcoma	9.73e-05	0.00133	CcSEcCtD
Bosutinib—Renal failure—Epirubicin—sarcoma	9.71e-05	0.00133	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Etoposide—sarcoma	9.7e-05	0.00133	CcSEcCtD
Bosutinib—Asthenia—Mitoxantrone—sarcoma	9.69e-05	0.00133	CcSEcCtD
Bosutinib—Fatigue—Etoposide—sarcoma	9.69e-05	0.00133	CcSEcCtD
Bosutinib—Pain—Etoposide—sarcoma	9.61e-05	0.00132	CcSEcCtD
Bosutinib—Neutropenia—Doxorubicin—sarcoma	9.59e-05	0.00131	CcSEcCtD
Bosutinib—Upper respiratory tract infection—Doxorubicin—sarcoma	9.53e-05	0.00131	CcSEcCtD
Bosutinib—Diarrhoea—Vincristine—sarcoma	9.49e-05	0.0013	CcSEcCtD
Bosutinib—Hepatobiliary disease—Epirubicin—sarcoma	9.34e-05	0.00128	CcSEcCtD
Bosutinib—Nausea—Thiotepa—sarcoma	9.29e-05	0.00127	CcSEcCtD
Bosutinib—Feeling abnormal—Etoposide—sarcoma	9.26e-05	0.00127	CcSEcCtD
Bosutinib—Diarrhoea—Mitoxantrone—sarcoma	9.24e-05	0.00127	CcSEcCtD
Bosutinib—Nausea—Dactinomycin—sarcoma	9.22e-05	0.00126	CcSEcCtD
Bosutinib—Agranulocytosis—Epirubicin—sarcoma	9.22e-05	0.00126	CcSEcCtD
Bosutinib—Pneumonia—Doxorubicin—sarcoma	9.19e-05	0.00126	CcSEcCtD
Bosutinib—Gastrointestinal pain—Etoposide—sarcoma	9.19e-05	0.00126	CcSEcCtD
Bosutinib—Dizziness—Vincristine—sarcoma	9.17e-05	0.00126	CcSEcCtD
Bosutinib—Infestation—Doxorubicin—sarcoma	9.14e-05	0.00125	CcSEcCtD
Bosutinib—Infestation NOS—Doxorubicin—sarcoma	9.14e-05	0.00125	CcSEcCtD
Bosutinib—DMPK—lymph node—sarcoma	9.03e-05	0.000829	CbGeAlD
Bosutinib—MAP4K4—testis—sarcoma	9.02e-05	0.000828	CbGeAlD
Bosutinib—TBK1—tendon—sarcoma	9e-05	0.000826	CbGeAlD
Bosutinib—PTK2—tendon—sarcoma	9e-05	0.000826	CbGeAlD
Bosutinib—MAP4K5—cardiac atrium—sarcoma	9e-05	0.000826	CbGeAlD
Bosutinib—MAP3K3—cardiac atrium—sarcoma	9e-05	0.000826	CbGeAlD
Bosutinib—Renal failure—Doxorubicin—sarcoma	8.98e-05	0.00123	CcSEcCtD
Bosutinib—MAP2K2—bone marrow—sarcoma	8.97e-05	0.000823	CbGeAlD
Bosutinib—ULK3—bone marrow—sarcoma	8.97e-05	0.000823	CbGeAlD
Bosutinib—BCR—testis—sarcoma	8.95e-05	0.000822	CbGeAlD
Bosutinib—NUAK2—testis—sarcoma	8.95e-05	0.000822	CbGeAlD
Bosutinib—MAP4K5—uterus—sarcoma	8.95e-05	0.000821	CbGeAlD
Bosutinib—Urticaria—Etoposide—sarcoma	8.93e-05	0.00122	CcSEcCtD
Bosutinib—MAP3K2—bone marrow—sarcoma	8.91e-05	0.000817	CbGeAlD
Bosutinib—MAP3K12—testis—sarcoma	8.89e-05	0.000816	CbGeAlD
Bosutinib—Abdominal pain—Etoposide—sarcoma	8.88e-05	0.00122	CcSEcCtD
Bosutinib—Body temperature increased—Etoposide—sarcoma	8.88e-05	0.00122	CcSEcCtD
Bosutinib—Hepatitis—Epirubicin—sarcoma	8.87e-05	0.00122	CcSEcCtD
Bosutinib—BMPR2—liver—sarcoma	8.86e-05	0.000813	CbGeAlD
Bosutinib—IRAK1—tendon—sarcoma	8.83e-05	0.00081	CbGeAlD
Bosutinib—MAP3K7—bone marrow—sarcoma	8.82e-05	0.00081	CbGeAlD
Bosutinib—Vomiting—Vincristine—sarcoma	8.82e-05	0.00121	CcSEcCtD
Bosutinib—PDGFRB—seminal vesicle—sarcoma	8.82e-05	0.000809	CbGeAlD
Bosutinib—STK36—liver—sarcoma	8.79e-05	0.000806	CbGeAlD
Bosutinib—Urinary tract disorder—Epirubicin—sarcoma	8.76e-05	0.0012	CcSEcCtD
Bosutinib—Rash—Vincristine—sarcoma	8.75e-05	0.0012	CcSEcCtD
Bosutinib—Dermatitis—Vincristine—sarcoma	8.74e-05	0.0012	CcSEcCtD
Bosutinib—Oedema peripheral—Epirubicin—sarcoma	8.74e-05	0.0012	CcSEcCtD
Bosutinib—TBK1—bone marrow—sarcoma	8.72e-05	0.0008	CbGeAlD
Bosutinib—Connective tissue disorder—Epirubicin—sarcoma	8.71e-05	0.00119	CcSEcCtD
Bosutinib—MAP2K1—testis—sarcoma	8.71e-05	0.000799	CbGeAlD
Bosutinib—STK35—testis—sarcoma	8.71e-05	0.000799	CbGeAlD
Bosutinib—ABL1—myometrium—sarcoma	8.7e-05	0.000798	CbGeAlD
Bosutinib—Urethral disorder—Epirubicin—sarcoma	8.69e-05	0.00119	CcSEcCtD
Bosutinib—Headache—Vincristine—sarcoma	8.69e-05	0.00119	CcSEcCtD
Bosutinib—MERTK—liver—sarcoma	8.69e-05	0.000797	CbGeAlD
Bosutinib—RPS6KB1—tendon—sarcoma	8.66e-05	0.000795	CbGeAlD
Bosutinib—CSK—testis—sarcoma	8.65e-05	0.000794	CbGeAlD
Bosutinib—Hepatobiliary disease—Doxorubicin—sarcoma	8.64e-05	0.00119	CcSEcCtD
Bosutinib—STK25—lymph node—sarcoma	8.63e-05	0.000792	CbGeAlD
Bosutinib—FGR—tendon—sarcoma	8.61e-05	0.00079	CbGeAlD
Bosutinib—CSNK1A1—testis—sarcoma	8.6e-05	0.000789	CbGeAlD
Bosutinib—Vomiting—Mitoxantrone—sarcoma	8.59e-05	0.00118	CcSEcCtD
Bosutinib—AXL—tendon—sarcoma	8.58e-05	0.000787	CbGeAlD
Bosutinib—EPHA3—lymph node—sarcoma	8.56e-05	0.000786	CbGeAlD
Bosutinib—EPHA2—lymphoid tissue—sarcoma	8.55e-05	0.000785	CbGeAlD
Bosutinib—IRAK1—bone marrow—sarcoma	8.55e-05	0.000785	CbGeAlD
Bosutinib—HCK—testis—sarcoma	8.54e-05	0.000784	CbGeAlD
Bosutinib—CLK1—testis—sarcoma	8.54e-05	0.000784	CbGeAlD
Bosutinib—FYN—lymphoid tissue—sarcoma	8.54e-05	0.000783	CbGeAlD
Bosutinib—Agranulocytosis—Doxorubicin—sarcoma	8.53e-05	0.00117	CcSEcCtD
Bosutinib—MAP4K4—liver—sarcoma	8.53e-05	0.000782	CbGeAlD
Bosutinib—Rash—Mitoxantrone—sarcoma	8.52e-05	0.00117	CcSEcCtD
Bosutinib—Dermatitis—Mitoxantrone—sarcoma	8.51e-05	0.00117	CcSEcCtD
Bosutinib—ABL2—testis—sarcoma	8.49e-05	0.000779	CbGeAlD
Bosutinib—BCR—liver—sarcoma	8.47e-05	0.000777	CbGeAlD
Bosutinib—NUAK2—liver—sarcoma	8.47e-05	0.000777	CbGeAlD
Bosutinib—Headache—Mitoxantrone—sarcoma	8.46e-05	0.00116	CcSEcCtD
Bosutinib—MAP3K12—liver—sarcoma	8.41e-05	0.000771	CbGeAlD
Bosutinib—CSK—Daunorubicin—Epirubicin—sarcoma	8.4e-05	0.0269	CbGdCrCtD
Bosutinib—CSK—Doxorubicin—Epirubicin—sarcoma	8.4e-05	0.0269	CbGdCrCtD
Bosutinib—RPS6KB1—bone marrow—sarcoma	8.39e-05	0.00077	CbGeAlD
Bosutinib—PLK2—lymph node—sarcoma	8.39e-05	0.00077	CbGeAlD
Bosutinib—CAMK2G—testis—sarcoma	8.38e-05	0.000769	CbGeAlD
Bosutinib—BMP2K—testis—sarcoma	8.38e-05	0.000769	CbGeAlD
Bosutinib—Erythema multiforme—Epirubicin—sarcoma	8.38e-05	0.00115	CcSEcCtD
Bosutinib—PDGFRB—hematopoietic system—sarcoma	8.38e-05	0.000769	CbGeAlD
Bosutinib—ABL1—embryo—sarcoma	8.37e-05	0.000768	CbGeAlD
Bosutinib—MAP4K5—lymphoid tissue—sarcoma	8.34e-05	0.000766	CbGeAlD
Bosutinib—FGR—bone marrow—sarcoma	8.34e-05	0.000765	CbGeAlD
Bosutinib—LCK—bone marrow—sarcoma	8.34e-05	0.000765	CbGeAlD
Bosutinib—SIK3—lymph node—sarcoma	8.33e-05	0.000764	CbGeAlD
Bosutinib—CSF1R—smooth muscle tissue—sarcoma	8.33e-05	0.000764	CbGeAlD
Bosutinib—YES1—cardiac atrium—sarcoma	8.31e-05	0.000763	CbGeAlD
Bosutinib—LRRK2—testis—sarcoma	8.31e-05	0.000762	CbGeAlD
Bosutinib—EGFR—testis—sarcoma	8.29e-05	0.00076	CbGeAlD
Bosutinib—Tinnitus—Epirubicin—sarcoma	8.27e-05	0.00113	CcSEcCtD
Bosutinib—YES1—uterus—sarcoma	8.27e-05	0.000759	CbGeAlD
Bosutinib—SLK—tendon—sarcoma	8.25e-05	0.000757	CbGeAlD
Bosutinib—Nausea—Vincristine—sarcoma	8.24e-05	0.00113	CcSEcCtD
Bosutinib—MAP2K1—liver—sarcoma	8.23e-05	0.000756	CbGeAlD
Bosutinib—STK35—liver—sarcoma	8.23e-05	0.000756	CbGeAlD
Bosutinib—Cardiac disorder—Epirubicin—sarcoma	8.23e-05	0.00113	CcSEcCtD
Bosutinib—CSF1R—skin of body—sarcoma	8.22e-05	0.000754	CbGeAlD
Bosutinib—Hepatitis—Doxorubicin—sarcoma	8.2e-05	0.00112	CcSEcCtD
Bosutinib—TAOK3—cardiac atrium—sarcoma	8.2e-05	0.000753	CbGeAlD
Bosutinib—EPHB4—tendon—sarcoma	8.2e-05	0.000752	CbGeAlD
Bosutinib—STK10—uterus—sarcoma	8.19e-05	0.000752	CbGeAlD
Bosutinib—CSK—liver—sarcoma	8.18e-05	0.000751	CbGeAlD
Bosutinib—TAOK3—uterus—sarcoma	8.16e-05	0.000749	CbGeAlD
Bosutinib—CSNK1A1—liver—sarcoma	8.13e-05	0.000746	CbGeAlD
Bosutinib—CHEK2—Vinblastine—Vincristine—sarcoma	8.11e-05	0.026	CbGdCrCtD
Bosutinib—Urinary tract disorder—Doxorubicin—sarcoma	8.1e-05	0.00111	CcSEcCtD
Bosutinib—PTK2B—testis—sarcoma	8.1e-05	0.000743	CbGeAlD
Bosutinib—Oedema peripheral—Doxorubicin—sarcoma	8.08e-05	0.00111	CcSEcCtD
Bosutinib—HCK—liver—sarcoma	8.08e-05	0.000741	CbGeAlD
Bosutinib—CLK1—liver—sarcoma	8.08e-05	0.000741	CbGeAlD
Bosutinib—PDGFRB—connective tissue—sarcoma	8.07e-05	0.000741	CbGeAlD
Bosutinib—Asthenia—Etoposide—sarcoma	8.06e-05	0.00111	CcSEcCtD
Bosutinib—Connective tissue disorder—Doxorubicin—sarcoma	8.06e-05	0.00111	CcSEcCtD
Bosutinib—Urethral disorder—Doxorubicin—sarcoma	8.04e-05	0.0011	CcSEcCtD
Bosutinib—EPHA2—tendon—sarcoma	8.04e-05	0.000738	CbGeAlD
Bosutinib—FYN—tendon—sarcoma	8.03e-05	0.000736	CbGeAlD
Bosutinib—Nausea—Mitoxantrone—sarcoma	8.03e-05	0.0011	CcSEcCtD
Bosutinib—ABL2—liver—sarcoma	8.02e-05	0.000736	CbGeAlD
Bosutinib—STK4—lymph node—sarcoma	8.02e-05	0.000736	CbGeAlD
Bosutinib—Immune system disorder—Epirubicin—sarcoma	8.01e-05	0.0011	CcSEcCtD
Bosutinib—SLK—bone marrow—sarcoma	8e-05	0.000734	CbGeAlD
Bosutinib—SRC—cardiac atrium—sarcoma	7.99e-05	0.000734	CbGeAlD
Bosutinib—Mediastinal disorder—Epirubicin—sarcoma	7.99e-05	0.0011	CcSEcCtD
Bosutinib—CSNK1E—testis—sarcoma	7.97e-05	0.000731	CbGeAlD
Bosutinib—Pruritus—Etoposide—sarcoma	7.95e-05	0.00109	CcSEcCtD
Bosutinib—EPHB4—bone marrow—sarcoma	7.94e-05	0.000728	CbGeAlD
Bosutinib—BMP2K—liver—sarcoma	7.93e-05	0.000727	CbGeAlD
Bosutinib—CAMK2G—liver—sarcoma	7.93e-05	0.000727	CbGeAlD
Bosutinib—CAMK1D—lymph node—sarcoma	7.92e-05	0.000727	CbGeAlD
Bosutinib—ABL1—seminal vesicle—sarcoma	7.86e-05	0.000721	CbGeAlD
Bosutinib—LRRK2—liver—sarcoma	7.86e-05	0.000721	CbGeAlD
Bosutinib—MAP3K3—tendon—sarcoma	7.84e-05	0.00072	CbGeAlD
Bosutinib—MAP4K5—tendon—sarcoma	7.84e-05	0.00072	CbGeAlD
Bosutinib—SIK1—testis—sarcoma	7.84e-05	0.00072	CbGeAlD
Bosutinib—IRAK4—testis—sarcoma	7.84e-05	0.00072	CbGeAlD
Bosutinib—STK24—lymph node—sarcoma	7.83e-05	0.000719	CbGeAlD
Bosutinib—EGFR—liver—sarcoma	7.83e-05	0.000719	CbGeAlD
Bosutinib—FYN—bone marrow—sarcoma	7.77e-05	0.000713	CbGeAlD
Bosutinib—CSK—Epirubicin—Doxorubicin—sarcoma	7.77e-05	0.0249	CbGdCrCtD
Bosutinib—CSK—Daunorubicin—Doxorubicin—sarcoma	7.77e-05	0.0249	CbGdCrCtD
Bosutinib—EPHA4—testis—sarcoma	7.76e-05	0.000712	CbGeAlD
Bosutinib—Erythema multiforme—Doxorubicin—sarcoma	7.76e-05	0.00106	CcSEcCtD
Bosutinib—Malnutrition—Epirubicin—sarcoma	7.72e-05	0.00106	CcSEcCtD
Bosutinib—YES1—lymphoid tissue—sarcoma	7.71e-05	0.000707	CbGeAlD
Bosutinib—Diarrhoea—Etoposide—sarcoma	7.69e-05	0.00105	CcSEcCtD
Bosutinib—ERBB3—testis—sarcoma	7.69e-05	0.000705	CbGeAlD
Bosutinib—ULK3—testis—sarcoma	7.67e-05	0.000704	CbGeAlD
Bosutinib—MAP2K2—testis—sarcoma	7.67e-05	0.000704	CbGeAlD
Bosutinib—PTK2B—liver—sarcoma	7.66e-05	0.000702	CbGeAlD
Bosutinib—Tinnitus—Doxorubicin—sarcoma	7.65e-05	0.00105	CcSEcCtD
Bosutinib—STK10—lymphoid tissue—sarcoma	7.64e-05	0.000701	CbGeAlD
Bosutinib—Cardiac disorder—Doxorubicin—sarcoma	7.61e-05	0.00104	CcSEcCtD
Bosutinib—MAP3K2—testis—sarcoma	7.61e-05	0.000699	CbGeAlD
Bosutinib—TAOK3—lymphoid tissue—sarcoma	7.61e-05	0.000698	CbGeAlD
Bosutinib—MAP4K5—bone marrow—sarcoma	7.6e-05	0.000697	CbGeAlD
Bosutinib—MAP3K3—bone marrow—sarcoma	7.6e-05	0.000697	CbGeAlD
Bosutinib—FER—lymph node—sarcoma	7.58e-05	0.000695	CbGeAlD
Bosutinib—ALK—lymph node—sarcoma	7.58e-05	0.000695	CbGeAlD
Bosutinib—Dysgeusia—Epirubicin—sarcoma	7.56e-05	0.00104	CcSEcCtD
Bosutinib—MAP3K7—testis—sarcoma	7.54e-05	0.000692	CbGeAlD
Bosutinib—CSNK1E—liver—sarcoma	7.53e-05	0.000691	CbGeAlD
Bosutinib—ABL1—hematopoietic system—sarcoma	7.47e-05	0.000686	CbGeAlD
Bosutinib—Back pain—Epirubicin—sarcoma	7.47e-05	0.00102	CcSEcCtD
Bosutinib—PTK2—testis—sarcoma	7.46e-05	0.000684	CbGeAlD
Bosutinib—TBK1—testis—sarcoma	7.46e-05	0.000684	CbGeAlD
Bosutinib—Dizziness—Etoposide—sarcoma	7.43e-05	0.00102	CcSEcCtD
Bosutinib—MAP4K1—lymph node—sarcoma	7.43e-05	0.000681	CbGeAlD
Bosutinib—SIK1—liver—sarcoma	7.41e-05	0.00068	CbGeAlD
Bosutinib—IRAK4—liver—sarcoma	7.41e-05	0.00068	CbGeAlD
Bosutinib—SRC—lymphoid tissue—sarcoma	7.41e-05	0.00068	CbGeAlD
Bosutinib—Immune system disorder—Doxorubicin—sarcoma	7.41e-05	0.00102	CcSEcCtD
Bosutinib—Mediastinal disorder—Doxorubicin—sarcoma	7.39e-05	0.00101	CcSEcCtD
Bosutinib—BTK—lymph node—sarcoma	7.39e-05	0.000678	CbGeAlD
Bosutinib—PDGFRB—smooth muscle tissue—sarcoma	7.38e-05	0.000678	CbGeAlD
Bosutinib—MAP2K5—cardiac atrium—sarcoma	7.35e-05	0.000675	CbGeAlD
Bosutinib—IRAK1—testis—sarcoma	7.31e-05	0.000671	CbGeAlD
Bosutinib—PDGFRB—skin of body—sarcoma	7.29e-05	0.000669	CbGeAlD
Bosutinib—TNK2—lymph node—sarcoma	7.28e-05	0.000668	CbGeAlD
Bosutinib—ERBB3—liver—sarcoma	7.27e-05	0.000667	CbGeAlD
Bosutinib—MAP2K2—liver—sarcoma	7.25e-05	0.000665	CbGeAlD
Bosutinib—ULK3—liver—sarcoma	7.25e-05	0.000665	CbGeAlD
Bosutinib—YES1—tendon—sarcoma	7.24e-05	0.000665	CbGeAlD
Bosutinib—MAP3K2—liver—sarcoma	7.2e-05	0.00066	CbGeAlD
Bosutinib—ABL1—connective tissue—sarcoma	7.19e-05	0.00066	CbGeAlD
Bosutinib—MAP4K2—lymph node—sarcoma	7.18e-05	0.000659	CbGeAlD
Bosutinib—STK10—tendon—sarcoma	7.18e-05	0.000659	CbGeAlD
Bosutinib—CSF1R—cardiac atrium—sarcoma	7.18e-05	0.000659	CbGeAlD
Bosutinib—RPS6KB1—testis—sarcoma	7.17e-05	0.000658	CbGeAlD
Bosutinib—Ill-defined disorder—Epirubicin—sarcoma	7.16e-05	0.000982	CcSEcCtD
Bosutinib—TAOK3—tendon—sarcoma	7.15e-05	0.000656	CbGeAlD
Bosutinib—Vomiting—Etoposide—sarcoma	7.15e-05	0.00098	CcSEcCtD
Bosutinib—Malnutrition—Doxorubicin—sarcoma	7.14e-05	0.000979	CcSEcCtD
Bosutinib—CSF1R—uterus—sarcoma	7.14e-05	0.000655	CbGeAlD
Bosutinib—Anaemia—Epirubicin—sarcoma	7.13e-05	0.000978	CcSEcCtD
Bosutinib—MAP3K7—liver—sarcoma	7.13e-05	0.000654	CbGeAlD
Bosutinib—FGR—testis—sarcoma	7.13e-05	0.000654	CbGeAlD
Bosutinib—LCK—testis—sarcoma	7.13e-05	0.000654	CbGeAlD
Bosutinib—AXL—testis—sarcoma	7.1e-05	0.000652	CbGeAlD
Bosutinib—Rash—Etoposide—sarcoma	7.09e-05	0.000972	CcSEcCtD
Bosutinib—STK3—lymph node—sarcoma	7.08e-05	0.00065	CbGeAlD
Bosutinib—Dermatitis—Etoposide—sarcoma	7.08e-05	0.000971	CcSEcCtD
Bosutinib—PTK2—liver—sarcoma	7.05e-05	0.000647	CbGeAlD
Bosutinib—TBK1—liver—sarcoma	7.05e-05	0.000647	CbGeAlD
Bosutinib—Headache—Etoposide—sarcoma	7.04e-05	0.000965	CcSEcCtD
Bosutinib—YES1—bone marrow—sarcoma	7.02e-05	0.000644	CbGeAlD
Bosutinib—Dysgeusia—Doxorubicin—sarcoma	6.99e-05	0.000959	CcSEcCtD
Bosutinib—Malaise—Epirubicin—sarcoma	6.96e-05	0.000954	CcSEcCtD
Bosutinib—STK10—bone marrow—sarcoma	6.95e-05	0.000638	CbGeAlD
Bosutinib—TAOK3—bone marrow—sarcoma	6.93e-05	0.000636	CbGeAlD
Bosutinib—IRAK1—liver—sarcoma	6.91e-05	0.000634	CbGeAlD
Bosutinib—Leukopenia—Epirubicin—sarcoma	6.91e-05	0.000947	CcSEcCtD
Bosutinib—Back pain—Doxorubicin—sarcoma	6.91e-05	0.000947	CcSEcCtD
Bosutinib—SLK—testis—sarcoma	6.84e-05	0.000627	CbGeAlD
Bosutinib—BMPR2—lymph node—sarcoma	6.79e-05	0.000623	CbGeAlD
Bosutinib—EPHB4—testis—sarcoma	6.79e-05	0.000623	CbGeAlD
Bosutinib—RPS6KB1—liver—sarcoma	6.78e-05	0.000622	CbGeAlD
Bosutinib—LCK—liver—sarcoma	6.74e-05	0.000618	CbGeAlD
Bosutinib—FGR—liver—sarcoma	6.74e-05	0.000618	CbGeAlD
Bosutinib—STK36—lymph node—sarcoma	6.74e-05	0.000618	CbGeAlD
Bosutinib—EPHB3—lymph node—sarcoma	6.74e-05	0.000618	CbGeAlD
Bosutinib—Cough—Epirubicin—sarcoma	6.74e-05	0.000924	CcSEcCtD
Bosutinib—AXL—liver—sarcoma	6.71e-05	0.000616	CbGeAlD
Bosutinib—Nausea—Etoposide—sarcoma	6.68e-05	0.000915	CcSEcCtD
Bosutinib—MERTK—lymph node—sarcoma	6.66e-05	0.000611	CbGeAlD
Bosutinib—EPHA2—testis—sarcoma	6.66e-05	0.000611	CbGeAlD
Bosutinib—CSF1R—lymphoid tissue—sarcoma	6.65e-05	0.000611	CbGeAlD
Bosutinib—FYN—testis—sarcoma	6.65e-05	0.00061	CbGeAlD
Bosutinib—Ill-defined disorder—Doxorubicin—sarcoma	6.63e-05	0.000909	CcSEcCtD
Bosutinib—Anaemia—Doxorubicin—sarcoma	6.6e-05	0.000905	CcSEcCtD
Bosutinib—ABL1—smooth muscle tissue—sarcoma	6.58e-05	0.000604	CbGeAlD
Bosutinib—Myalgia—Epirubicin—sarcoma	6.57e-05	0.000901	CcSEcCtD
Bosutinib—Arthralgia—Epirubicin—sarcoma	6.57e-05	0.000901	CcSEcCtD
Bosutinib—Chest pain—Epirubicin—sarcoma	6.57e-05	0.000901	CcSEcCtD
Bosutinib—MAP4K4—lymph node—sarcoma	6.54e-05	0.0006	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	6.53e-05	0.000895	CcSEcCtD
Bosutinib—ABL1—skin of body—sarcoma	6.5e-05	0.000596	CbGeAlD
Bosutinib—MAP4K5—testis—sarcoma	6.49e-05	0.000596	CbGeAlD
Bosutinib—MAP3K3—testis—sarcoma	6.49e-05	0.000596	CbGeAlD
Bosutinib—Discomfort—Epirubicin—sarcoma	6.49e-05	0.00089	CcSEcCtD
Bosutinib—BCR—lymph node—sarcoma	6.49e-05	0.000596	CbGeAlD
Bosutinib—NUAK2—lymph node—sarcoma	6.49e-05	0.000596	CbGeAlD
Bosutinib—SLK—liver—sarcoma	6.46e-05	0.000593	CbGeAlD
Bosutinib—MAP3K12—lymph node—sarcoma	6.44e-05	0.000591	CbGeAlD
Bosutinib—Malaise—Doxorubicin—sarcoma	6.44e-05	0.000883	CcSEcCtD
Bosutinib—EPHB4—liver—sarcoma	6.42e-05	0.000589	CbGeAlD
Bosutinib—MAP2K5—tendon—sarcoma	6.41e-05	0.000588	CbGeAlD
Bosutinib—Leukopenia—Doxorubicin—sarcoma	6.39e-05	0.000877	CcSEcCtD
Bosutinib—PDGFRB—cardiac atrium—sarcoma	6.37e-05	0.000584	CbGeAlD
Bosutinib—PDGFRB—uterus—sarcoma	6.33e-05	0.000581	CbGeAlD
Bosutinib—STK35—lymph node—sarcoma	6.31e-05	0.000579	CbGeAlD
Bosutinib—MAP2K1—lymph node—sarcoma	6.31e-05	0.000579	CbGeAlD
Bosutinib—Anaphylactic shock—Epirubicin—sarcoma	6.3e-05	0.000864	CcSEcCtD
Bosutinib—Oedema—Epirubicin—sarcoma	6.3e-05	0.000864	CcSEcCtD
Bosutinib—EPHA2—liver—sarcoma	6.29e-05	0.000577	CbGeAlD
Bosutinib—FYN—liver—sarcoma	6.28e-05	0.000577	CbGeAlD
Bosutinib—CSK—lymph node—sarcoma	6.27e-05	0.000576	CbGeAlD
Bosutinib—Infection—Epirubicin—sarcoma	6.26e-05	0.000858	CcSEcCtD
Bosutinib—CSF1R—tendon—sarcoma	6.26e-05	0.000574	CbGeAlD
Bosutinib—Cough—Doxorubicin—sarcoma	6.23e-05	0.000855	CcSEcCtD
Bosutinib—CSNK1A1—lymph node—sarcoma	6.23e-05	0.000572	CbGeAlD
Bosutinib—HCK—lymph node—sarcoma	6.19e-05	0.000568	CbGeAlD
Bosutinib—CLK1—lymph node—sarcoma	6.19e-05	0.000568	CbGeAlD
Bosutinib—Nervous system disorder—Epirubicin—sarcoma	6.18e-05	0.000847	CcSEcCtD
Bosutinib—Thrombocytopenia—Epirubicin—sarcoma	6.17e-05	0.000846	CcSEcCtD
Bosutinib—ABL2—lymph node—sarcoma	6.15e-05	0.000565	CbGeAlD
Bosutinib—CHEK2—Doxorubicin—Epirubicin—sarcoma	6.15e-05	0.0197	CbGdCrCtD
Bosutinib—MAP3K3—liver—sarcoma	6.14e-05	0.000563	CbGeAlD
Bosutinib—MAP4K5—liver—sarcoma	6.14e-05	0.000563	CbGeAlD
Bosutinib—Skin disorder—Epirubicin—sarcoma	6.12e-05	0.000839	CcSEcCtD
Bosutinib—Arthralgia—Doxorubicin—sarcoma	6.08e-05	0.000834	CcSEcCtD
Bosutinib—Myalgia—Doxorubicin—sarcoma	6.08e-05	0.000834	CcSEcCtD
Bosutinib—Chest pain—Doxorubicin—sarcoma	6.08e-05	0.000834	CcSEcCtD
Bosutinib—CAMK2G—lymph node—sarcoma	6.08e-05	0.000558	CbGeAlD
Bosutinib—BMP2K—lymph node—sarcoma	6.08e-05	0.000558	CbGeAlD
Bosutinib—CSF1R—bone marrow—sarcoma	6.06e-05	0.000556	CbGeAlD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	6.04e-05	0.000828	CcSEcCtD
Bosutinib—LRRK2—lymph node—sarcoma	6.02e-05	0.000553	CbGeAlD
Bosutinib—Discomfort—Doxorubicin—sarcoma	6.01e-05	0.000824	CcSEcCtD
Bosutinib—EGFR—lymph node—sarcoma	6.01e-05	0.000551	CbGeAlD
Bosutinib—YES1—testis—sarcoma	6e-05	0.00055	CbGeAlD
Bosutinib—STK10—testis—sarcoma	5.94e-05	0.000545	CbGeAlD
Bosutinib—TAOK3—testis—sarcoma	5.92e-05	0.000543	CbGeAlD
Bosutinib—PDGFRB—lymphoid tissue—sarcoma	5.9e-05	0.000542	CbGeAlD
Bosutinib—PTK2B—lymph node—sarcoma	5.87e-05	0.000539	CbGeAlD
Bosutinib—ABL1—Idarubicin—Epirubicin—sarcoma	5.87e-05	0.0188	CbGdCrCtD
Bosutinib—ABL1—Doxorubicin—Epirubicin—sarcoma	5.87e-05	0.0188	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Epirubicin—sarcoma	5.87e-05	0.0188	CbGdCrCtD
Bosutinib—Oedema—Doxorubicin—sarcoma	5.83e-05	0.000799	CcSEcCtD
Bosutinib—Anaphylactic shock—Doxorubicin—sarcoma	5.83e-05	0.000799	CcSEcCtD
Bosutinib—Infection—Doxorubicin—sarcoma	5.79e-05	0.000794	CcSEcCtD
Bosutinib—CSNK1E—lymph node—sarcoma	5.77e-05	0.00053	CbGeAlD
Bosutinib—SRC—testis—sarcoma	5.77e-05	0.000529	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Epirubicin—sarcoma	5.74e-05	0.000787	CcSEcCtD
Bosutinib—Nervous system disorder—Doxorubicin—sarcoma	5.72e-05	0.000784	CcSEcCtD
Bosutinib—Thrombocytopenia—Doxorubicin—sarcoma	5.71e-05	0.000783	CcSEcCtD
Bosutinib—CHEK2—Epirubicin—Doxorubicin—sarcoma	5.69e-05	0.0182	CbGdCrCtD
Bosutinib—SIK1—lymph node—sarcoma	5.68e-05	0.000522	CbGeAlD
Bosutinib—IRAK4—lymph node—sarcoma	5.68e-05	0.000522	CbGeAlD
Bosutinib—ABL1—cardiac atrium—sarcoma	5.67e-05	0.000521	CbGeAlD
Bosutinib—YES1—liver—sarcoma	5.67e-05	0.00052	CbGeAlD
Bosutinib—Skin disorder—Doxorubicin—sarcoma	5.66e-05	0.000776	CcSEcCtD
Bosutinib—ABL1—uterus—sarcoma	5.64e-05	0.000518	CbGeAlD
Bosutinib—EPHA4—lymph node—sarcoma	5.63e-05	0.000516	CbGeAlD
Bosutinib—STK10—liver—sarcoma	5.62e-05	0.000516	CbGeAlD
Bosutinib—Dyspnoea—Epirubicin—sarcoma	5.62e-05	0.00077	CcSEcCtD
Bosutinib—TAOK3—liver—sarcoma	5.6e-05	0.000514	CbGeAlD
Bosutinib—ERBB3—lymph node—sarcoma	5.57e-05	0.000511	CbGeAlD
Bosutinib—ULK3—lymph node—sarcoma	5.56e-05	0.00051	CbGeAlD
Bosutinib—MAP2K2—lymph node—sarcoma	5.56e-05	0.00051	CbGeAlD
Bosutinib—PDGFRB—tendon—sarcoma	5.55e-05	0.000509	CbGeAlD
Bosutinib—MAP3K2—lymph node—sarcoma	5.52e-05	0.000506	CbGeAlD
Bosutinib—Decreased appetite—Epirubicin—sarcoma	5.48e-05	0.000751	CcSEcCtD
Bosutinib—MAP3K7—lymph node—sarcoma	5.47e-05	0.000502	CbGeAlD
Bosutinib—SRC—liver—sarcoma	5.45e-05	0.000501	CbGeAlD
Bosutinib—Gastrointestinal disorder—Epirubicin—sarcoma	5.44e-05	0.000746	CcSEcCtD
Bosutinib—Fatigue—Epirubicin—sarcoma	5.43e-05	0.000745	CcSEcCtD
Bosutinib—ABL1—Epirubicin—Doxorubicin—sarcoma	5.43e-05	0.0174	CbGdCrCtD
Bosutinib—ABL1—Daunorubicin—Doxorubicin—sarcoma	5.43e-05	0.0174	CbGdCrCtD
Bosutinib—ABL1—Idarubicin—Doxorubicin—sarcoma	5.43e-05	0.0174	CbGdCrCtD
Bosutinib—PTK2—lymph node—sarcoma	5.4e-05	0.000496	CbGeAlD
Bosutinib—TBK1—lymph node—sarcoma	5.4e-05	0.000496	CbGeAlD
Bosutinib—Pain—Epirubicin—sarcoma	5.39e-05	0.000739	CcSEcCtD
Bosutinib—PDGFRB—bone marrow—sarcoma	5.37e-05	0.000493	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Doxorubicin—sarcoma	5.31e-05	0.000728	CcSEcCtD
Bosutinib—MAP2K5—testis—sarcoma	5.31e-05	0.000487	CbGeAlD
Bosutinib—IRAK1—lymph node—sarcoma	5.3e-05	0.000486	CbGeAlD
Bosutinib—ABL1—lymphoid tissue—sarcoma	5.26e-05	0.000483	CbGeAlD
Bosutinib—RPS6KB1—lymph node—sarcoma	5.2e-05	0.000477	CbGeAlD
Bosutinib—Dyspnoea—Doxorubicin—sarcoma	5.2e-05	0.000713	CcSEcCtD
Bosutinib—Feeling abnormal—Epirubicin—sarcoma	5.19e-05	0.000712	CcSEcCtD
Bosutinib—CSF1R—testis—sarcoma	5.18e-05	0.000475	CbGeAlD
Bosutinib—LCK—lymph node—sarcoma	5.17e-05	0.000474	CbGeAlD
Bosutinib—FGR—lymph node—sarcoma	5.17e-05	0.000474	CbGeAlD
Bosutinib—Gastrointestinal pain—Epirubicin—sarcoma	5.15e-05	0.000706	CcSEcCtD
Bosutinib—AXL—lymph node—sarcoma	5.15e-05	0.000472	CbGeAlD
Bosutinib—Decreased appetite—Doxorubicin—sarcoma	5.07e-05	0.000695	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Doxorubicin—sarcoma	5.03e-05	0.00069	CcSEcCtD
Bosutinib—Fatigue—Doxorubicin—sarcoma	5.03e-05	0.000689	CcSEcCtD
Bosutinib—MAP2K5—liver—sarcoma	5.02e-05	0.00046	CbGeAlD
Bosutinib—Urticaria—Epirubicin—sarcoma	5e-05	0.000686	CcSEcCtD
Bosutinib—Pain—Doxorubicin—sarcoma	4.98e-05	0.000683	CcSEcCtD
Bosutinib—Abdominal pain—Epirubicin—sarcoma	4.98e-05	0.000683	CcSEcCtD
Bosutinib—Body temperature increased—Epirubicin—sarcoma	4.98e-05	0.000683	CcSEcCtD
Bosutinib—SLK—lymph node—sarcoma	4.95e-05	0.000455	CbGeAlD
Bosutinib—ABL1—tendon—sarcoma	4.95e-05	0.000454	CbGeAlD
Bosutinib—EPHB4—lymph node—sarcoma	4.92e-05	0.000451	CbGeAlD
Bosutinib—CSF1R—liver—sarcoma	4.9e-05	0.000449	CbGeAlD
Bosutinib—EPHA2—lymph node—sarcoma	4.83e-05	0.000443	CbGeAlD
Bosutinib—FYN—lymph node—sarcoma	4.82e-05	0.000442	CbGeAlD
Bosutinib—Feeling abnormal—Doxorubicin—sarcoma	4.8e-05	0.000659	CcSEcCtD
Bosutinib—ABL1—bone marrow—sarcoma	4.79e-05	0.00044	CbGeAlD
Bosutinib—Gastrointestinal pain—Doxorubicin—sarcoma	4.77e-05	0.000654	CcSEcCtD
Bosutinib—MAP4K5—lymph node—sarcoma	4.71e-05	0.000432	CbGeAlD
Bosutinib—MAP3K3—lymph node—sarcoma	4.71e-05	0.000432	CbGeAlD
Bosutinib—Urticaria—Doxorubicin—sarcoma	4.63e-05	0.000635	CcSEcCtD
Bosutinib—Abdominal pain—Doxorubicin—sarcoma	4.61e-05	0.000632	CcSEcCtD
Bosutinib—Body temperature increased—Doxorubicin—sarcoma	4.61e-05	0.000632	CcSEcCtD
Bosutinib—PDGFRB—testis—sarcoma	4.59e-05	0.000422	CbGeAlD
Bosutinib—Asthenia—Epirubicin—sarcoma	4.52e-05	0.00062	CcSEcCtD
Bosutinib—Pruritus—Epirubicin—sarcoma	4.46e-05	0.000611	CcSEcCtD
Bosutinib—YES1—lymph node—sarcoma	4.35e-05	0.000399	CbGeAlD
Bosutinib—PDGFRB—liver—sarcoma	4.34e-05	0.000399	CbGeAlD
Bosutinib—Diarrhoea—Epirubicin—sarcoma	4.31e-05	0.000591	CcSEcCtD
Bosutinib—STK10—lymph node—sarcoma	4.31e-05	0.000395	CbGeAlD
Bosutinib—TAOK3—lymph node—sarcoma	4.29e-05	0.000394	CbGeAlD
Bosutinib—SRC—lymph node—sarcoma	4.18e-05	0.000384	CbGeAlD
Bosutinib—Asthenia—Doxorubicin—sarcoma	4.18e-05	0.000573	CcSEcCtD
Bosutinib—Dizziness—Epirubicin—sarcoma	4.17e-05	0.000571	CcSEcCtD
Bosutinib—Pruritus—Doxorubicin—sarcoma	4.12e-05	0.000565	CcSEcCtD
Bosutinib—ABL1—testis—sarcoma	4.09e-05	0.000376	CbGeAlD
Bosutinib—Vomiting—Epirubicin—sarcoma	4.01e-05	0.000549	CcSEcCtD
Bosutinib—Diarrhoea—Doxorubicin—sarcoma	3.99e-05	0.000547	CcSEcCtD
Bosutinib—Rash—Epirubicin—sarcoma	3.97e-05	0.000545	CcSEcCtD
Bosutinib—Dermatitis—Epirubicin—sarcoma	3.97e-05	0.000544	CcSEcCtD
Bosutinib—Headache—Epirubicin—sarcoma	3.95e-05	0.000541	CcSEcCtD
Bosutinib—ABL1—liver—sarcoma	3.87e-05	0.000355	CbGeAlD
Bosutinib—Dizziness—Doxorubicin—sarcoma	3.85e-05	0.000529	CcSEcCtD
Bosutinib—MAP2K5—lymph node—sarcoma	3.85e-05	0.000353	CbGeAlD
Bosutinib—CSF1R—lymph node—sarcoma	3.75e-05	0.000345	CbGeAlD
Bosutinib—Nausea—Epirubicin—sarcoma	3.74e-05	0.000513	CcSEcCtD
Bosutinib—Vomiting—Doxorubicin—sarcoma	3.71e-05	0.000508	CcSEcCtD
Bosutinib—Rash—Doxorubicin—sarcoma	3.68e-05	0.000504	CcSEcCtD
Bosutinib—Dermatitis—Doxorubicin—sarcoma	3.67e-05	0.000503	CcSEcCtD
Bosutinib—Headache—Doxorubicin—sarcoma	3.65e-05	0.000501	CcSEcCtD
Bosutinib—Nausea—Doxorubicin—sarcoma	3.46e-05	0.000475	CcSEcCtD
Bosutinib—PDGFRB—lymph node—sarcoma	3.33e-05	0.000306	CbGeAlD
Bosutinib—CYP3A4—hematopoietic system—sarcoma	3.28e-05	0.000301	CbGeAlD
Bosutinib—ABL1—lymph node—sarcoma	2.97e-05	0.000272	CbGeAlD
Bosutinib—ABCB1—myometrium—sarcoma	2.71e-05	0.000248	CbGeAlD
Bosutinib—ABCB1—embryo—sarcoma	2.6e-05	0.000239	CbGeAlD
Bosutinib—ABCB1—seminal vesicle—sarcoma	2.44e-05	0.000224	CbGeAlD
Bosutinib—ABCB1—hematopoietic system—sarcoma	2.32e-05	0.000213	CbGeAlD
Bosutinib—ABCB1—uterus—sarcoma	1.76e-05	0.000161	CbGeAlD
Bosutinib—CYP3A4—liver—sarcoma	1.7e-05	0.000156	CbGeAlD
Bosutinib—ABCB1—lymphoid tissue—sarcoma	1.64e-05	0.00015	CbGeAlD
Bosutinib—ABCB1—bone marrow—sarcoma	1.49e-05	0.000137	CbGeAlD
Bosutinib—ABCB1—testis—sarcoma	1.27e-05	0.000117	CbGeAlD
Bosutinib—ABCB1—liver—sarcoma	1.2e-05	0.00011	CbGeAlD
Bosutinib—ABCB1—lymph node—sarcoma	9.23e-06	8.47e-05	CbGeAlD
Bosutinib—MAP2K1—Disease—SRC—sarcoma	1.01e-06	6.31e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—EGFR—sarcoma	1e-06	6.27e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—EGFR—sarcoma	1e-06	6.27e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KIT—sarcoma	1e-06	6.25e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—NRAS—sarcoma	1e-06	6.25e-06	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—HRAS—sarcoma	1e-06	6.25e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—EGFR—sarcoma	1e-06	6.25e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL2—sarcoma	9.92e-07	6.2e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—KRAS—sarcoma	9.92e-07	6.2e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—MYC—sarcoma	9.9e-07	6.18e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—KRAS—sarcoma	9.85e-07	6.15e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—SRC—sarcoma	9.83e-07	6.14e-06	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—HRAS—sarcoma	9.8e-07	6.12e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—EGFR—sarcoma	9.8e-07	6.12e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—NRAS—sarcoma	9.78e-07	6.11e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—EGFR—sarcoma	9.76e-07	6.09e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—NRAS—sarcoma	9.73e-07	6.07e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—CTNNB1—sarcoma	9.72e-07	6.07e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MDM2—sarcoma	9.71e-07	6.06e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—SRC—sarcoma	9.7e-07	6.06e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—KRAS—sarcoma	9.69e-07	6.05e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—MYC—sarcoma	9.68e-07	6.05e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—EGFR—sarcoma	9.68e-07	6.05e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CCND1—sarcoma	9.67e-07	6.04e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—JUN—sarcoma	9.65e-07	6.03e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KIT—sarcoma	9.65e-07	6.03e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—EGFR—sarcoma	9.65e-07	6.03e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MDM2—sarcoma	9.61e-07	6e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—EGFR—sarcoma	9.6e-07	5.99e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—CTNNB1—sarcoma	9.58e-07	5.98e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—VEGFA—sarcoma	9.58e-07	5.98e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CREB1—sarcoma	9.53e-07	5.95e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—SRC—sarcoma	9.51e-07	5.94e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—KRAS—sarcoma	9.49e-07	5.93e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—KRAS—sarcoma	9.49e-07	5.93e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—EGFR—sarcoma	9.47e-07	5.92e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MDM2—sarcoma	9.47e-07	5.92e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—NRAS—sarcoma	9.46e-07	5.91e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—KRAS—sarcoma	9.46e-07	5.91e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—MYC—sarcoma	9.45e-07	5.9e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—VEGFA—sarcoma	9.44e-07	5.9e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—HRAS—sarcoma	9.43e-07	5.89e-06	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—HRAS—sarcoma	9.42e-07	5.88e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—CTNNB1—sarcoma	9.36e-07	5.85e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—NRAS—sarcoma	9.33e-07	5.83e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL2—sarcoma	9.3e-07	5.81e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KDR—sarcoma	9.27e-07	5.79e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MDM2—sarcoma	9.27e-07	5.79e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—KRAS—sarcoma	9.26e-07	5.78e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—EGFR—sarcoma	9.24e-07	5.77e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—TP53—sarcoma	9.22e-07	5.76e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—KRAS—sarcoma	9.22e-07	5.76e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—SRC—sarcoma	9.2e-07	5.74e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CREB1—sarcoma	9.19e-07	5.74e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—SRC—sarcoma	9.17e-07	5.72e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—NRAS—sarcoma	9.15e-07	5.71e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—KRAS—sarcoma	9.15e-07	5.71e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MDM2—sarcoma	9.13e-07	5.7e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—KRAS—sarcoma	9.12e-07	5.69e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—MYC—sarcoma	9.11e-07	5.69e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—TP53—sarcoma	9.09e-07	5.68e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MDM2—sarcoma	9.08e-07	5.67e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—KRAS—sarcoma	9.07e-07	5.66e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—MYC—sarcoma	9.06e-07	5.66e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—JUN—sarcoma	9.05e-07	5.65e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—HRAS—sarcoma	9.02e-07	5.63e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—CTNNB1—sarcoma	8.98e-07	5.61e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—VEGFA—sarcoma	8.96e-07	5.59e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—KRAS—sarcoma	8.95e-07	5.59e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—EGFR—sarcoma	8.91e-07	5.56e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—EGFR—sarcoma	8.86e-07	5.53e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—NRAS—sarcoma	8.85e-07	5.53e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—HRAS—sarcoma	8.82e-07	5.51e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—NRAS—sarcoma	8.82e-07	5.51e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—MYC—sarcoma	8.81e-07	5.5e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—SRC—sarcoma	8.78e-07	5.48e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—TP53—sarcoma	8.75e-07	5.47e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—KRAS—sarcoma	8.73e-07	5.45e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—HRAS—sarcoma	8.69e-07	5.43e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—MYC—sarcoma	8.69e-07	5.43e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL2—sarcoma	8.67e-07	5.42e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—SRC—sarcoma	8.66e-07	5.41e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—KRAS—sarcoma	8.62e-07	5.38e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—EGFR—sarcoma	8.62e-07	5.38e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KIT—sarcoma	8.54e-07	5.34e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—EGFR—sarcoma	8.5e-07	5.31e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL2—sarcoma	8.46e-07	5.29e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—SRC—sarcoma	8.46e-07	5.29e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CCND1—sarcoma	8.45e-07	5.28e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—NRAS—sarcoma	8.45e-07	5.28e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—JUN—sarcoma	8.44e-07	5.27e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—HRAS—sarcoma	8.43e-07	5.27e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—VEGFA—sarcoma	8.43e-07	5.27e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—TP53—sarcoma	8.43e-07	5.27e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—TP53—sarcoma	8.43e-07	5.27e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—KRAS—sarcoma	8.42e-07	5.26e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CTNNB1—sarcoma	8.37e-07	5.23e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—HRAS—sarcoma	8.37e-07	5.23e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—KRAS—sarcoma	8.37e-07	5.23e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—NRAS—sarcoma	8.33e-07	5.2e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—CTNNB1—sarcoma	8.29e-07	5.18e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL2—sarcoma	8.29e-07	5.17e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CCND1—sarcoma	8.25e-07	5.15e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—MYC—sarcoma	8.24e-07	5.15e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—HRAS—sarcoma	8.24e-07	5.14e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—JUN—sarcoma	8.23e-07	5.14e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CTNNB1—sarcoma	8.17e-07	5.1e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL2—sarcoma	8.16e-07	5.09e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—NRAS—sarcoma	8.14e-07	5.08e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—KRAS—sarcoma	8.14e-07	5.08e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CREB1—sarcoma	8.13e-07	5.08e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—TP53—sarcoma	8.13e-07	5.08e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ENO2—sarcoma	8.12e-07	5.07e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL2—sarcoma	8.11e-07	5.07e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CCND1—sarcoma	8.08e-07	5.04e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HBA1—sarcoma	8.07e-07	5.04e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—HRAS—sarcoma	8.07e-07	5.04e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—HRAS—sarcoma	8.07e-07	5.04e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—EGFR—sarcoma	8.06e-07	5.03e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—JUN—sarcoma	8.06e-07	5.03e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—HRAS—sarcoma	8.04e-07	5.02e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—EGFR—sarcoma	8.03e-07	5.02e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—KRAS—sarcoma	8.03e-07	5.01e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CTNNB1—sarcoma	8e-07	5e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CCND1—sarcoma	7.95e-07	4.97e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—JUN—sarcoma	7.94e-07	4.96e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CCND1—sarcoma	7.91e-07	4.94e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—JUN—sarcoma	7.89e-07	4.93e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MDM2—sarcoma	7.89e-07	4.93e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—KRAS—sarcoma	7.88e-07	4.92e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CTNNB1—sarcoma	7.87e-07	4.92e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—HRAS—sarcoma	7.87e-07	4.92e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—MYC—sarcoma	7.87e-07	4.91e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—HRAS—sarcoma	7.83e-07	4.89e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CTNNB1—sarcoma	7.83e-07	4.89e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—NRAS—sarcoma	7.81e-07	4.88e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—HRAS—sarcoma	7.77e-07	4.86e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—MYC—sarcoma	7.76e-07	4.85e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—HRAS—sarcoma	7.75e-07	4.84e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—HRAS—sarcoma	7.71e-07	4.81e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—KRAS—sarcoma	7.61e-07	4.76e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—HRAS—sarcoma	7.61e-07	4.75e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MDM2—sarcoma	7.6e-07	4.75e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EGFR—sarcoma	7.59e-07	4.74e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—KRAS—sarcoma	7.59e-07	4.74e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—MYC—sarcoma	7.58e-07	4.74e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—SRC—sarcoma	7.57e-07	4.73e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—HRAS—sarcoma	7.42e-07	4.64e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—EGFR—sarcoma	7.42e-07	4.63e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—SRC—sarcoma	7.38e-07	4.61e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VEGFA—sarcoma	7.37e-07	4.6e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—HRAS—sarcoma	7.33e-07	4.58e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NRAS—sarcoma	7.28e-07	4.55e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—KRAS—sarcoma	7.27e-07	4.54e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TP53—sarcoma	7.24e-07	4.52e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—SRC—sarcoma	7.23e-07	4.52e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—NRAS—sarcoma	7.21e-07	4.5e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—sarcoma	7.19e-07	4.49e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—KRAS—sarcoma	7.17e-07	4.48e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—HRAS—sarcoma	7.15e-07	4.47e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TP53—sarcoma	7.14e-07	4.46e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—SRC—sarcoma	7.12e-07	4.45e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—HRAS—sarcoma	7.12e-07	4.44e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EGFR—sarcoma	7.11e-07	4.44e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NRAS—sarcoma	7.1e-07	4.44e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—SRC—sarcoma	7.08e-07	4.42e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL2—sarcoma	7.05e-07	4.4e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—sarcoma	7.04e-07	4.4e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—KRAS—sarcoma	7.01e-07	4.38e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NRAS—sarcoma	6.96e-07	4.34e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—sarcoma	6.93e-07	4.33e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—HRAS—sarcoma	6.92e-07	4.32e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—sarcoma	6.9e-07	4.31e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PLCG1—sarcoma	6.89e-07	4.3e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CCND1—sarcoma	6.87e-07	4.29e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—JUN—sarcoma	6.86e-07	4.28e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NRAS—sarcoma	6.85e-07	4.28e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—HRAS—sarcoma	6.82e-07	4.26e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NRAS—sarcoma	6.81e-07	4.25e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CTNNB1—sarcoma	6.8e-07	4.25e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL2—sarcoma	6.79e-07	4.24e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MYC—sarcoma	6.78e-07	4.24e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TP53—sarcoma	6.77e-07	4.23e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MDM2—sarcoma	6.73e-07	4.2e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—KRAS—sarcoma	6.72e-07	4.2e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—MYC—sarcoma	6.71e-07	4.19e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—HRAS—sarcoma	6.69e-07	4.18e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EGFR—sarcoma	6.63e-07	4.14e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCND1—sarcoma	6.62e-07	4.14e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MYC—sarcoma	6.62e-07	4.13e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—JUN—sarcoma	6.61e-07	4.13e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EGFR—sarcoma	6.57e-07	4.1e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CTNNB1—sarcoma	6.56e-07	4.09e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MYC—sarcoma	6.48e-07	4.05e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EGFR—sarcoma	6.47e-07	4.04e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—HRAS—sarcoma	6.47e-07	4.04e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—HRAS—sarcoma	6.45e-07	4.03e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MYC—sarcoma	6.38e-07	3.98e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TP53—sarcoma	6.37e-07	3.98e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MYC—sarcoma	6.34e-07	3.96e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EGFR—sarcoma	6.34e-07	3.96e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—KRAS—sarcoma	6.27e-07	3.91e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EGFR—sarcoma	6.24e-07	3.9e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EGFR—sarcoma	6.21e-07	3.88e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—KRAS—sarcoma	6.2e-07	3.87e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—HRAS—sarcoma	6.18e-07	3.86e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—SRC—sarcoma	6.15e-07	3.84e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—KRAS—sarcoma	6.11e-07	3.82e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—HRAS—sarcoma	6.09e-07	3.81e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL2—sarcoma	6.01e-07	3.76e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—sarcoma	5.99e-07	3.74e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—KRAS—sarcoma	5.99e-07	3.74e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—HRAS—sarcoma	5.96e-07	3.72e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SRC—sarcoma	5.93e-07	3.7e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NRAS—sarcoma	5.92e-07	3.69e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—KRAS—sarcoma	5.89e-07	3.68e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—KRAS—sarcoma	5.86e-07	3.66e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCND1—sarcoma	5.86e-07	3.66e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—JUN—sarcoma	5.85e-07	3.65e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CTNNB1—sarcoma	5.8e-07	3.63e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—sarcoma	5.77e-07	3.6e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—HRAS—sarcoma	5.71e-07	3.57e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NRAS—sarcoma	5.7e-07	3.56e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TP53—sarcoma	5.57e-07	3.48e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MYC—sarcoma	5.51e-07	3.44e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TP53—sarcoma	5.43e-07	3.39e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—HRAS—sarcoma	5.33e-07	3.33e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TP53—sarcoma	5.32e-07	3.32e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MYC—sarcoma	5.31e-07	3.32e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—HRAS—sarcoma	5.27e-07	3.29e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TP53—sarcoma	5.24e-07	3.27e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TP53—sarcoma	5.21e-07	3.25e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—HRAS—sarcoma	5.2e-07	3.25e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EGFR—sarcoma	5.19e-07	3.24e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—sarcoma	5.11e-07	3.19e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—KRAS—sarcoma	5.09e-07	3.18e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—HRAS—sarcoma	5.09e-07	3.18e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NRAS—sarcoma	5.05e-07	3.15e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—HRAS—sarcoma	5.01e-07	3.13e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—HRAS—sarcoma	4.98e-07	3.11e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—KRAS—sarcoma	4.91e-07	3.06e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MYC—sarcoma	4.7e-07	2.94e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGFR—sarcoma	4.6e-07	2.87e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TP53—sarcoma	4.53e-07	2.83e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TP53—sarcoma	4.36e-07	2.72e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—KRAS—sarcoma	4.34e-07	2.71e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—HRAS—sarcoma	4.33e-07	2.7e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—HRAS—sarcoma	4.17e-07	2.6e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TP53—sarcoma	3.86e-07	2.41e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—HRAS—sarcoma	3.69e-07	2.31e-06	CbGpPWpGaD
